Chun Yan | Stem Cell Research | Best Researcher Award

Posted on by Cell Biologist

Dr. Chun Yan | Stem Cell Research | Best Researcher Award

Dr. Chun Yan, Department of Thoracic Surgery, Zhongshan Hospital of Xiamen University, China

Dr. Yan Chun is an Attending Physician at the School of Medicine/Zhongshan Hospital, Xiamen University. With a solid foundation in clinical medicine and surgery, Dr. Chun brings over a decade of experience in thoracic oncology and AI-driven medical research. After earning a Bachelor’s degree from Fujian Medical University, he pursued his Master’s in Surgery at Shanghai Jiao Tong University. Since 2018, Dr. Chun has contributed significantly to clinical practice, medical innovation, and academic research. His current focus includes AI-assisted diagnosis, radiogenomics, and the biomechanics of thoracic surgery. A recognized member of the Minimally Invasive Thoracic Oncology Committee under the Fujian Primary Health Association, he has received multiple accolades for his pioneering work in esophageal cancer therapy. Dr. Chun’s commitment to precision medicine and integration of AI in healthcare highlights his suitability for prestigious research honors and positions him as a leader in translational medical research in China.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Academic Foundation: Dr. Yan Chun holds a Master’s degree in Surgery from Shanghai Jiao Tong University and a Bachelor’s degree in Clinical Medicine, ensuring a robust foundation in both research and clinical practice.

  2. Innovative Research: He leads and participates in cutting-edge projects that integrate AI, radiogenomics, and biomechanical modeling, reflecting a multidisciplinary and forward-thinking approach.

  3. Recognized Excellence: His work has been honored with regional innovation and scientific progress awards, demonstrating tangible contributions to thoracic oncology.

  4. Clinical Expertise: With 7+ years of medical experience, including as an attending physician, he bridges practical medicine with impactful research.

  5. Leadership Role: Serving on a professional committee in minimally invasive thoracic oncology highlights his thought leadership within his specialty.

🧠 Areas for Improvement:

  1. Expanded Publication Record: While impactful, Dr. Chun’s publication portfolio would benefit from a broader presence in international, high-impact journals to boost academic visibility.

  2. International Collaboration: Engaging in cross-border research partnerships could enhance both innovation scope and influence.

  3. Grant Scale: Existing grants are modest in size. Applying for national-level or larger competitive grants could support more ambitious projects.

  4. Mentorship and Training: Documenting roles in mentoring junior researchers or medical students would strengthen his academic leadership profile.

🎓 Education:

Dr. Yan Chun’s academic journey began with a Bachelor of Clinical Medicine (MBBS) from Fujian Medical University (2010–2015), where he gained fundamental clinical knowledge and medical training. He then advanced his specialization in surgery by completing a Master of Surgery (MS) at Shanghai Jiao Tong University (2015–2018), one of China’s top medical institutions. His education emphasized evidence-based clinical practice, surgical skills, and research methodology. During his postgraduate studies, he was actively involved in academic projects, laying a strong foundation for his later research in thoracic oncology and artificial intelligence in medicine. This robust educational background equips him with interdisciplinary expertise, bridging clinical medicine, surgical techniques, and research innovation—especially in radiogenomics and perioperative therapies for esophageal cancer. His training reflects both academic rigor and a forward-looking approach to integrating emerging technologies with healthcare delivery, making him well-prepared to drive impactful research initiatives.

💼 Experience:

Dr. Yan Chun has held progressive roles at Zhongshan Hospital, Xiamen University since 2018. Starting as a Physician (2018–2023), he delivered comprehensive clinical care while engaging in translational research projects. Since July 2023, he has been serving as an Attending Physician, contributing to surgical excellence and AI-assisted diagnostic strategies in thoracic oncology. His hands-on clinical experience is complemented by leadership in grant-funded research, particularly in predictive modeling and biomechanics. Dr. Chun’s involvement in multi-disciplinary teams, collaborations with AI scientists, and contributions to surgical innovation have advanced the care standards in thoracic surgery. He has also actively contributed to institutional and provincial-level scientific programs, showcasing his capability in both practical medicine and medical research. His work stands at the intersection of clinical practice and innovation, and he remains committed to improving outcomes for patients with complex thoracic conditions through precision diagnostics and minimally invasive techniques.

🏅 Awards and Honors:

Dr. Yan Chun has received multiple accolades recognizing his innovative contributions to thoracic oncology and surgical AI. His project, “AI-Assisted Precision Perioperative Individualized Therapy for Esophageal Cancer”, was selected as one of the Top Ten Innovations of the Year by the Xiamen Hospital Association, highlighting its impact on personalized medicine. Another landmark project, “Precision Diagnosis and Treatment Paradigm for Esophageal Squamous Cell Carcinoma Driven by AI and Multi-Omics Integration”, earned him the Third Prize for Scientific and Technological Progress from the Fujian Anti-Cancer Association, underscoring his leadership in advanced cancer care. His awards reflect not only clinical innovation but also excellence in multi-disciplinary research. These honors are a testament to his ability to bridge clinical needs with technological advancements, demonstrating vision, technical skill, and translational impact. They position him as a high-impact researcher contributing meaningfully to China’s evolving healthcare landscape.

🔬 Research Focus:

Dr. Yan Chun’s research is primarily centered on the integration of artificial intelligence, radiogenomics, and thoracic oncology. He leads a government-funded project investigating deep learning-based predictive models for lymph node metastasis and prognosis in esophageal cancer, leveraging imaging-genomics to improve pre- and post-operative decision-making. He also contributed to biomechanical analysis of the NUSS procedure for pectus excavatum, applying finite element modeling to improve surgical outcomes. His work merges clinical data science, image processing, and genomics, aiming to build personalized treatment pathways and enhance minimally invasive approaches. Dr. Chun’s interdisciplinary approach reflects a deep understanding of both computational technologies and real-world clinical challenges. His ambition is to develop AI-powered platforms that augment oncological diagnostics and optimize surgical interventions. Through a combination of hands-on experience and research rigor, he is at the forefront of precision medicine in thoracic surgery, striving for innovation that is both data-driven and patient-centered.

📚 Publications Top Notes:

📖 Association between per- and polyfluoroalkyl substances exposure and prevalence of chronic obstructive pulmonary disease: The mediating role of serum albumin – Science of the Total Environment, 2024 🌱🫁

🧾 Conclusion:

Dr. Yan Chun demonstrates exceptional promise and maturity as a clinical researcher whose work lies at the confluence of AI, precision medicine, and thoracic surgery. His contributions to the diagnosis and treatment of esophageal cancer through radiogenomic modeling and minimally invasive techniques are both innovative and clinically meaningful. Backed by professional recognition and a strong clinical research ethic, Dr. Chun is a worthy candidate for the Best Researcher Award. With expanded international presence and high-impact publications, he is poised to become a leading figure in the global thoracic oncology research community.

Francesco Gaudio | Stem Cell Research | Best Researcher Award

Posted on by Cell Biologist

Prof. Francesco Gaudio | Stem Cell Research | Best Researcher Award

Prof. Francesco Gaudio, LUM UNIVERSITY, Italy

Prof. Francesco Gaudio is a highly accomplished hematologist with over 20 years of clinical and academic expertise, specializing in lymphoproliferative neoplasms and hematopoietic stem cell transplantation. Currently serving as Assistant Professor in Hematology at University LUM Giuseppe Degennaro and a practicing medical doctor at “F. Miulli” Hospital, he has previously held long-term roles at renowned Italian hospitals. With a prolific research record, he has authored over 50 publications in high-impact journals and contributed more than 100 abstracts to international conferences. He has conducted research in leading global institutions, including Memorial Sloan-Kettering and Imperial College. Alongside clinical innovation, he is a passionate educator and experienced healthcare manager. His focus on therapeutic advances and multidisciplinary care makes him a leader in hematology research and oncology care.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Clinical and Academic Experience
    Over 20 years of dedicated work in hematology, with expertise in lymphoproliferative disorders and hematopoietic stem cell transplantation.

  2. Robust Research Profile

    • More than 50 peer-reviewed publications in Impact Factor journals.

    • 100+ abstracts presented internationally.

    • Principal and co-investigator in multinational clinical studies.

  3. Global Exposure & Collaborations
    Research training and collaborations at globally recognized centers:

    • Memorial Sloan-Kettering (USA)

    • Imperial College (UK)

    • Lyon Sud (France)

    • VHIO Barcelona (Spain)

  4. Commitment to Academic Growth

    • Teaches Blood Diseases, Oncology, and Pathology.

    • Holds National Scientific Qualification for Associate Professor level.

  5. Leadership & Management Training

    • Managerial courses from SDA Bocconi, ISTUD Foundation, and CURSUS.

  6. Multidisciplinary Impact
    Engages in translational research that bridges hematology, oncology, and emerging areas like cannabinoid therapies and survivorship in cancer.

⚠️ Areas for Improvement:

  1. Leadership in High-Impact Authorship
    While his contribution as co-author is commendable, increasing first or senior authorship in landmark studies would strengthen his research leadership visibility.

  2. Grant Leadership and Funding Acknowledgment
    No mention of competitive grant acquisition or principal leadership in major funded research networks; pursuing this could enhance academic competitiveness.

  3. Public Engagement and Open Science
    Could further boost impact by increasing participation in open-access platforms, public talks, and wider media dissemination of research findings.

🎓 Education:

Prof. Gaudio holds a Degree in Medicine and Surgery from the University of Bari (1995–1996), where he explored clonogenic hematopoietic activity in lymphoma patients. He specialized in Hematology (2001–2002), focusing on stem cell mobilization challenges. He further expanded his scientific foundation with a Postgraduate Specialization in Chemico-Pharmaceutical Research from CARSO (1998). Recognized for academic excellence, he earned the National Scientific Qualification (ASN) for Associate Professor in Hematology, Oncology, and Rheumatology in 2020. His academic path is complemented by top-tier executive and managerial training, including healthcare leadership programs from SDA Bocconi, ISTUD Foundation, and CURSUS. Early education includes a Classical High School Diploma from Liceo Classico ‘Quinto Ennio’, Taranto. His diverse education underscores a balanced mastery of clinical medicine, research, and institutional leadership.

💼 Professional Experience:

Prof. Gaudio’s medical journey spans over two decades in hematology and oncology. Since April 2024, he serves as an Assistant Professor at University LUM Giuseppe Degennaro and practices medicine at “F. Miulli” Regional Hospital. Prior to this, he was a senior hematologist at Policlinico Consorziale, AOU Bari for nearly 19 years, providing expert care and engaging in impactful research. He also worked at Ospedali Riuniti in Foggia, honing his clinical foundations. His experience includes leadership in clinical trials, management of complex hematologic malignancies, and therapeutic protocol development. He is a sought-after speaker, educator, and research collaborator with exposure to international institutions including Sloan-Kettering (USA), Imperial College (UK), and VHIO (Spain). His long-standing service and global outreach reflect deep dedication to patient care, academic excellence, and translational medicine.

🔬 Research Focus:

Prof. Gaudio’s research focuses on lymphomas, leukemias, and hematopoietic stem cell transplantation, combining clinical acumen with molecular innovation. As Principal Investigator in numerous global trials, he has helped shape advanced therapeutic strategies and enhance survival in hematological malignancies. His work delves into mobilization of CD34+ stem cells, radiotherapy-induced toxicity, and biological markers of malignancy. Recent systematic reviews explore epithelial–mesenchymal transcription factors, BPDCN, and the neurological impact of cannabidiol. His interests also span survivorship in Hodgkin lymphoma patients, with emphasis on long-term toxicity and risk evaluation. His teaching integrates updated scientific evidence into medical curricula, training the next generation of hematologists. International collaborations and cross-border research highlight his commitment to innovation and best practices in oncology. Prof. Gaudio’s work not only advances hematology but also bridges clinical gaps through interdisciplinary solutions.

📚 Publications Top Notes:

📄 Exploring the Role of Epithelial–Mesenchymal Transcriptional Factors Involved in Hematological Malignancy and Solid Tumors: A Systematic Review 🔬🧬

📄 Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity 🎗️📊

📄 Plerixafor in association with R-DHAP and G-CSF to mobilize a large number of CD34+ cells in patients with relapsed-refractory diffuse large B-cell lymphomas 🩸💉

📄 The Evolving Role of Cannabidiol-Rich Cannabis in People with Autism Spectrum Disorder: A Systematic Review 🌿🧠

📄 Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview 🔎🧫

📝 Conclusion:

Prof. Francesco Gaudio is a highly qualified and deserving candidate for the Best Researcher Award. His two decades of contribution to hematology and oncology, combined with a prolific publication record, international collaboration, and dedication to clinical innovation, clearly demonstrate excellence in medical research. While opportunities exist for expanded authorship leadership and grant visibility, his current achievements are deeply impactful and relevant to modern hematologic science. His work bridges bench-to-bedside approaches and continues to benefit both the scientific community and patient outcomes.

Philippe Menasché | Stem Cell Research | Best Researcher Award

Posted on by Cell Biologist

Prof. Philippe Menasché | Stem Cell Research | Best Researcher Award

Prof. Philippe Menasché, AP-HP, France

Prof. Philippe Menasché, born on August 10, 1950, is a pioneering French cardiovascular surgeon and regenerative medicine researcher. Renowned globally for his work in cell therapy and heart failure, he performed the world’s first fetal stem cell transplantation in a human heart. With over four decades in medicine, he has blended surgical excellence with translational research, bridging the gap between bench and bedside. A professor since 1988, his leadership spans multiple roles—from senior hospital surgeon to director of major research teams at INSERM and the Carpentier Foundation. He has served as scientific advisor to health authorities and remains an active contributor to high-impact publications and international collaborations. A recipient of prestigious honors such as the Prix Galien and the Earl Bakken Award, Prof. Menasché continues to shape the future of cardiovascular regenerative therapy.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Clinical Innovation

    • Performed the first-in-man fetal stem cell transplantation for cardiac repair.

    • Led translational research turning basic stem cell science into clinical applications.

  2. Extensive Academic and Research Leadership

    • Over four decades of experience as a cardiovascular surgeon and academic leader.

    • Directed major units at INSERM, Carpentier Foundation, and Paris Hospitals.

  3. Global Recognition and Awards

    • Recipient of highly prestigious scientific prizes such as the Prix Galien (2016) and Earl Bakken Award (2011).

    • Recognized by top French and international medical societies.

  4. Recent and Relevant Research Impact

    • Active contributor to multicenter trials including ISCHEMIA, STROMA-CoV-2, and TRAUMACELL.

    • Publications in high-impact journals on cardiac regeneration, cell therapy, and stem cell-derived secretomes.

  5. Leadership in Science Policy and Ethics

    • President of the Medical and Scientific Council at France’s Agency of Biomedicine.

    • Advisor to the French Minister of Health (2005–2007), influencing national bioethics and translational policy.

⚠️ Areas for Improvement:

  1. Broader International Integration

    • While internationally recognized, deeper ongoing collaboration with North American and Asian biomedical consortia could further elevate global influence.

    • The upcoming visiting professorship at Columbia University (2025) is a strong step in this direction.

  2. Integration of AI & Digital Health

    • Limited evidence of work in AI-guided regenerative medicine, machine learning in cardiac diagnostics, or digital health integration in therapeutic development.

    • These areas represent major future growth potential in cardiac care.

  3. Mentorship Visibility

    • While his scientific contributions are vast, greater emphasis on training and mentoring the next generation of clinician-scientists would bolster his legacy.

📚 Education:

Prof. Menasché’s academic foundation is rooted in two pillars of French higher education. He earned his Doctor of Medicine (MD) from the Faculté de Médecine de Paris in 1979, graduating with honors, including the coveted Internship Golden Medal. He then pursued deeper inquiry into biomedical science, culminating in a Doctorate in Science (PhD) from Université Paris-Orsay in 1987. His dual training in clinical medicine and scientific research provided the ideal springboard for a career that integrates patient care with innovation. In 1988, he became a Professor of Thoracic and Cardiovascular Surgery, reflecting his command of both technical skill and academic leadership. His scholarly progression has also led to visiting roles abroad, including a forthcoming appointment as Visiting Professor in Biomedical Engineering at Columbia University in 2025. This cross-disciplinary education empowers his unique contribution to both surgical practice and regenerative cardiovascular therapies.

🏥 Experience:

Prof. Menasché began his medical journey in 1973 as an intern in Paris hospitals, ascending to Senior Staff Surgeon in 1988—a position he still holds. From 1995 to 2007, he served as Director of Research at the Surgical School of the Greater Paris Academic Hospitals. His research leadership extended to INSERM, where he directed Unit U633 and co-led regenerative therapy teams. He headed the Laboratory of Biosurgical Research at the Carpentier Foundation from 2002 to 2018. In parallel, he has played influential roles on regulatory and advisory boards, including as President of the Medical and Scientific Council of France’s Agency of Biomedicine. A dedicated member of multiple medical and scientific societies, Prof. Menasché has edited prestigious journals and contributed to over a dozen major clinical trials and collaborative studies. His experience combines clinical excellence, institutional leadership, and innovative research in heart failure and cell therapy.

🧬 Research Focus:

Prof. Menasché’s research is centered on regenerative medicine for cardiovascular diseases, particularly using stem cells and secretomes to repair damaged heart tissue post-myocardial infarction. His team explores therapeutic strategies involving pluripotent stem cell-derived cardiomyocytes, mesenchymal stromal cells, and extracellular vesicles to promote myocardial regeneration and immune modulation. He has led pioneering first-in-human trials, including the use of cell-derived secretomes in heart failure patients. His investigations bridge fundamental science with translational application, often conducted in multicenter randomized controlled trials. His work also intersects with neurological conditions, such as traumatic brain injury, using cell-based therapies to address neuroinflammation. Prof. Menasché is also involved in evaluating the safety and efficacy of stem cell-based interventions in ARDS, including COVID-19-associated cases. A central member of the European Society of Cardiology’s regenerative medicine group, he is advancing personalized and precise treatments for heart failure through novel biologics and bioengineering tools.

📄 Publications Top Notes:

  1. 🫀 Revitalizing the heart: strategies and tools for cardiomyocyte regeneration post-myocardial infarction

  2. 💉 Trials and tribulations of cell therapy for heart failure: an update on ongoing trials

  3. 🫀📊 Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial

  4. 🧠🧪 Effects of intravascular administration of mesenchymal stromal cells…after traumatic brain injury (TRAUMACELL)

  5. 💓🧫 Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial

  6. 🦠🫁 Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells (STROMA-CoV-2)

  7. 🧬💗 Head-to-head comparison of relevant cell sources of small extracellular vesicles for cardiac repair

  8. 🫀💉 First-in-man use of a cardiovascular cell-derived secretome in heart failure – Case report

  9. 🧬🫀 Human PSC-derived cardiac cells and their products: therapies for cardiac repair

  10. 🫀🫄 Impact of Complete Revascularization in the ISCHEMIA Trial

📝 Conclusion:

Prof. Philippe Menasché is exceptionally qualified for the Best Researcher Award. His groundbreaking work in cardiac regeneration, commitment to translational medicine, and lasting contributions to surgical science and healthcare policy make him a uniquely impactful figure. His track record is not only defined by scientific innovation but also by societal relevance, particularly in addressing heart failure—a leading global health burden.

Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Prof. Dr. Sibel Elif Gultekin, Gazi University Faculty of Dentistry, Turkey

Prof. Dr. Sibel Elif Gültekin is a renowned academic and clinician in Oral Pathology and Periodontology at Gazi University Faculty of Dentistry, Türkiye. With over two decades of experience, she has significantly advanced molecular understanding of odontogenic tumors, HPV-induced oral lesions, and periodontal regeneration. Holding both DDS and Ph.D. degrees, she has led her department as Chair for 10 years and contributed globally as a visiting researcher and advisor. Her collaborations with institutions like the University of Cologne and UCSF reflect her international impact. She has published extensively in high-impact journals, authored books, and mentored numerous young researchers. Her dedication has been recognized through editorial appointments and professional society memberships. Prof. Gültekin’s translational research bridges pathology and clinical dentistry, making her a pioneer in the diagnosis and treatment of oral diseases.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Dual Specialization & Academic Leadership: Prof. Gültekin’s rare dual Ph.D. in Oral Pathology and Periodontology, along with her decade-long leadership as department chair, highlights deep academic and organizational expertise.

  2. High Research Output & Impact: With 96 publications, 50+ research projects, and citations exceeding 1300 (Google Scholar), her scholarly productivity and influence are clear. Her h-index across databases (14–17) confirms consistent academic contribution.

  3. Global Collaborations: Active collaborations with international centers like UCSF and University of Cologne underscore her role in global scientific advancement.

  4. Innovative Research Areas: She works at the forefront of molecular oncology, focusing on HPV-associated oral cancers, odontogenic tumors, and biomarkers like P16, VIM3, and PDCD4.

  5. Educational & Editorial Leadership: Served on scientific and editorial boards, symposiums, and advisory panels; she also authored 2 academic books and guided national congresses.

  6. Professional Societies: Active member of multiple esteemed societies (IAOP, ESP, EHNS, IADR), reflecting recognition in the international scientific community.

⚙️ Areas for Improvement:

  1. Clinical Translation Scaling: While her biomarker discoveries are notable, increasing efforts to lead translational clinical trials could accelerate therapeutic application.

  2. Policy Advocacy: Engaging more in international oral health policy or WHO-affiliated programs could amplify her impact beyond academia.

  3. Mentorship on Global Scale: Expanding formal international mentorship programs or fellowships could further cement her influence and legacy.

🎓 Education:

Prof. Dr. Sibel Elif Gültekin holds both DDS and Ph.D. degrees, specializing in Oral Pathology and Periodontology. She completed her undergraduate dental studies at Gazi University Faculty of Dentistry, where she later pursued her doctoral studies. Her academic training extended beyond Türkiye through international fellowships and research placements, including the prestigious Department of Medicine and Stomatology at the University of California San Francisco (UCSF) and the Institute for Pathology at the University of Cologne. Her educational journey is marked by an interdisciplinary approach, blending basic sciences and clinical applications. These robust academic foundations have positioned her as a global expert in oral cancer biomarkers, regenerative periodontology, and molecular pathology, nurturing future dentists and researchers through an integrative, evidence-based curriculum and global research exposure.

💼 Experience:

Prof. Dr. Gültekin has over 25 years of experience in dentistry, oral pathology, and periodontology. She has served as Professor and Chair of the Department of Oral Pathology at Gazi University, shaping both academic curricula and national diagnostic standards. Internationally, she collaborated with UCSF and the University of Cologne on pioneering projects in oral cancer and HPV research. Her clinical and academic background spans over 50 funded research projects, with 96 published papers in prestigious journals indexed by SCI, Scopus, and PubMed. She has contributed to oral health policy through editorial and advisory roles, including at journals like Journal of Oral Health Frontiers. Her expertise has guided scientific boards and symposia in Türkiye and beyond, particularly in head and neck pathology. She remains a sought-after consultant and reviewer, advocating for personalized medicine and molecular diagnostics in oral health.

🔬 Research Focus:

Prof. Dr. Sibel Elif Gültekin’s research centers on the molecular mechanisms of oral diseases, particularly odontogenic tumors, oral epithelial dysplasia, and HPV-induced carcinomas. She has made key contributions in identifying biomarkers such as P16, PDCD4, VIM3, and CD8+ T-cell infiltrates, enhancing early diagnosis and prognosis of oral and oropharyngeal cancers. Her research also explores microsatellite instability and loss of heterozygosity in oral squamous cell carcinoma. Additionally, she has contributed to periodontal tissue regeneration studies and the development of personalized therapeutic strategies. With over 1,300 citations and an h-index of 17 on Google Scholar, her impactful work bridges molecular science and clinical application. Collaborating with global experts in pathology, oncology, and molecular biology, Prof. Gültekin’s research not only contributes to academic literature but also informs clinical protocols and treatment pathways in modern dentistry and oral oncology.

📚 Publications Top Notes:

  • 🧬 Microsatellite Instability and Loss of Heterozygosity as Prognostic Markers in Oral Squamous Cell Carcinoma (Genes, Chromosomes and Cancer, 2024)

  • 🧪 Efficiency of B-RAF-/MEK-inhibitors in B-RAF Mutated Ameloblastoma: Case Report and Review (Heliyon, 2023)

  • 🦷 Kişiselleştirilmiş Diş Hekimliği (ADO Klinik Bilimler Dergisi, 2023)

  • 🔍 Apoptosis Related PDCD4: Promising Novel Biomarker for Early Detection of Oral Cancer (ADO Klinik Bilimler Dergisi, 2022)

  • 🛡️ PD-L1 Expression and High CD8+ Lymphocyte Infiltrate Predict Outcome in Oropharyngeal SCC (International Journal of Molecular Sciences, 2020)

🧾 Conclusion:

Prof. Dr. Sibel Elif Gültekin is a highly deserving nominee for the Best Researcher Award. Her pioneering contributions in oral pathology, particularly in molecular diagnostics and HPV-related oral oncology, place her at the forefront of dental research. Her exceptional academic record, leadership, and dedication to collaborative and translational science make her a standout candidate who embodies the spirit of innovation, mentorship, and global impact.

ALICIA MARIA TAMAYO CARBON | Stem Cell Research | Women Researcher Award

Posted on by Cell Biologist

Dr. ALICIA MARIA TAMAYO CARBON | Stem Cell Research | Women Researcher Award

Dr. ALICIA MARIA TAMAYO CARBON , HOSPITAL CLÍNICO QUIRÚRGICO HERMANOS AMEIJEIRAS , Cuba

Dra. C. Alicia María Tamayo Carbón is a highly accomplished specialist in plastic surgery and caumatology at the Hermanos Ameijeiras Clinical and Surgical Hospital in Cuba. With extensive academic and professional qualifications, she holds a medical degree, multiple specializations in comprehensive general medicine, plastic surgery, and caumatology, and is an expert in regenerative therapy. She is a researcher, professor, and author of numerous scientific papers and book chapters. Dra. Tamayo Carbón is recognized for her pioneering work in regenerative therapy using adipose tissue. She has received national recognition with awards like the National Impact Award from ANIR and the Meritorious Researcher Award from CIGB. Dra. Tamayo has collaborated with various institutions on groundbreaking research in regenerative medicine and gender reassignment. She is a prominent member of several professional organizations, contributing significantly to medical advancements in Cuba and beyond.

Publication Profile: 

Orcid

Strengths for the Award:

Dra. Alicia María Tamayo Carbón is an outstanding candidate for the Women Researcher Award due to her extensive contributions to the fields of plastic surgery, caumatology, and regenerative therapy. Her pioneering work in adipose tissue-based regenerative therapy has had a profound impact on the medical community, both nationally and internationally. With 11 ongoing research projects, 125 published journals, and significant collaborations with renowned institutions, her academic and clinical achievements have earned her multiple accolades such as the National Impact Award and Meritorious Researcher Award. Additionally, her leadership roles in scientific councils and her involvement in various groundbreaking projects highlight her influence and dedication to advancing medical practices, particularly in cosmetic and reconstructive surgery, as well as in gender reassignment. Her contributions have also led to the publication of books, patents, and a strong academic presence.

Areas for Improvement:

While Dra. Tamayo’s work is extensive and impactful, expanding her visibility in international collaborations outside of Cuba and increasing her citation index could enhance her global recognition. Further engagement in multidisciplinary collaborations, particularly in the areas of advanced technologies like AI or machine learning in surgery, could be explored to push the boundaries of her work in regenerative therapy.

Education:

Dra. Alicia María Tamayo Carbón’s academic journey reflects her dedication to advancing medical knowledge and practice. She began with a medical degree, followed by first-degree specialization in comprehensive general medicine. Her pursuit of excellence continued as she achieved both first- and second-degree specialization in plastic surgery and caumatology. Additionally, she holds a diploma in healthcare management and a university postgraduate degree in aesthetic medicine from the University of the Atlantic, Barcelona, Spain. Her academic foundation is complemented by a specialization in regenerative therapy, reinforcing her commitment to innovative treatments in her field. Dra. Tamayo Carbón’s academic achievements are paired with a passion for teaching, as she serves as a professor for the Master’s program in Aesthetic Medicine in Barcelona. Her educational path has laid the groundwork for her contributions to regenerative therapy and aesthetic medicine, making her a recognized expert in her field.

Experience:

Dra. Alicia María Tamayo Carbón boasts a rich professional background in plastic surgery and regenerative therapy. As a full professor and researcher, she has significantly contributed to the field of regenerative therapy, particularly in the use of adipose tissue for medical treatments. Her extensive experience is underscored by her clinical work at the Hermanos Ameijeiras Clinical and Surgical Hospital in Cuba. Dra. Tamayo has also held pivotal roles in national and international collaborations, including projects with the Cuban Institute of Hematology and Immunology and CEADEN, focusing on stem cell research and tissue engineering. She has been a key figure in developing regenerative therapy applications for skin disorders, gender reassignment, and reconstructive surgery. Her leadership as the head of the national specialty group and her board membership in the Cuban Society of Plastic Surgery and Caumatology further highlight her influence. Dra. Tamayo’s professional career is marked by continuous advancements in surgical and therapeutic techniques.

Research Focus:

Dra. Alicia María Tamayo Carbón’s research focus lies at the intersection of plastic surgery, regenerative medicine, and tissue engineering. Her groundbreaking work in regenerative therapy, particularly the use of adipose tissue and stem cells for medical treatments, has positioned her as a leader in this field. She has led numerous projects that explore adipose-derived stem cells, nanofat, and tissue engineering, particularly in reconstructive surgery, cosmetic procedures, and gender reassignment. Dra. Tamayo has collaborated with several national and international institutions to explore the phenotypic characterization of stem cells and their application in regenerative therapies. Her work also includes investigating new methods in tissue engineering, such as 3D bioprinting of biodegradable scaffolds for regenerative purposes. She has actively contributed to the development of clinical trials targeting stem cells from umbilical cord adipose tissue. Through her research, Dra. Tamayo Carbón aims to improve patient outcomes and advance the field of regenerative therapy in aesthetic and reconstructive surgery.

Publications Top Notes:

  1. “Utilidad del tejido adiposo en el tratamiento de las deformidades mentonianas. Un rescate de la lipotransferencia” 🦷💉
  2. “Identificación y caracterización de células madre hematopoyéticas en tejido adiposo obtenidas por nanograsa” 🧬🔬
  3. “Masculinización torácica aplicada al tratamiento de la ginecomastia grave” 💪🏽👨‍⚕️
  4. “Restauración volumétrica autóloga en pacientes con hemiatrofia adiposa facial” 🤲🏽💉
  5. “Mastoplastia de aumento, complemento indispensable de feminización en trastornos de identidad de género” 🌸🏥
  6. “Aplicación del protocolo de recuperación posquirúrgica mejorada en la liposucción abdominal” 💪🏼🛏️
  7. “Nanofat, su expansión en la asistencia médica” 🧴⚙️
  8. “Reconstrucción mamaria con colgajo dérmico en cirugía de lesión benigna con alto riesgo de malignidad” 💕🏥
  9. “Activation of the Immune System by Irresponsible use of Modeling Substances” 🦠⚠️
  10. “Tratamiento quirúrgico periorbitario, un enfoque desde la cirugía plástica” 👁️💉

Conclusion:

Dra. C. Alicia María Tamayo Carbón is an exemplary figure in the medical field, particularly in regenerative medicine and plastic surgery. Her groundbreaking research and continuous efforts to improve patient outcomes through innovative therapies make her a deserving candidate for the Research for Women Researcher Award. Her contributions have not only advanced scientific knowledge but also positively impacted clinical practices, demonstrating her exceptional commitment to both research and education. Dra. Tamayo’s expertise, leadership, and sustained contributions solidify her as a leader and an inspiration for future generations of female researchers.